Medtech company Distalmotion has secured a term loan facility of up to $70 million from Perceptive Advisors, an investment firm specialising in healthcare. The announcement was reported on 23 October 2026 by Startupticker.ch. The money is meant to speed up the roll-out of its DEXTER surgical robot in ambulatory surgery centres in the United States.
What Distalmotion's loan will finance
The financing has two goals, according to the company's press release. First, it is to strengthen Distalmotion's presence in the US market for ambulatory surgery centres, known as ASCs in the United States. Second, it is to fund the development of the DEXTER system and its range of instruments.
Chief executive Greg Roche speaks of additional capital to "accelerate" the company's growth strategy in the United States. He names three priorities:
- accelerating growth in the US market;
- strengthening the company's commercial presence;
- continuing to adapt DEXTER to patients, surgeons and ambulatory centre managers.
According to the press release, the financing builds on recent commercial momentum in the United States, where adoption of DEXTER is growing in ASCs. No figures, however, are given to measure this growth.
DEXTER, a surgical robot designed for outpatient care
DEXTER stands out first of all for its size. The company describes it as a compact, mobile system with flexible workflows, both in the operating room and for supply logistics. It is meant to let an ambulatory centre introduce robotic surgery without the infrastructure that traditional robotic platforms require.
The robot is cleared in the United States for the four most common outpatient soft-tissue procedures, among others:
- cholecystectomy, the removal of the gallbladder;
- inguinal hernia repair, in the groin;
- ventral hernia repair, on the abdominal wall;
- hysterectomy, the removal of the uterus.
Why the US outpatient market?
Distalmotion is betting on surgery moving out of hospitals. According to the press release, surgical care is migrating to outpatient settings, and ASCs are looking for robotic solutions suited to their constraints. Their priority is efficiency and the growth of their business.
Perceptive Advisors shares this view. "DEXTER is designed for the ongoing shift of high-volume surgery to ASCs, where efficiency is paramount," says Sam Chawla, portfolio manager at Perceptive. The press release, however, gives neither the size of this market nor the number of centres targeted.
Loan or funding round: what is the difference?
This financing is not a funding round. A round brings money into the company's equity in exchange for shares, as our guide to raising funds for a Swiss startup explains. Each round brings in new shareholders, and the founders' stake shrinks.
Distalmotion, by contrast, is borrowing. The press release refers to a "senior secured term loan facility", meaning a term loan facility that is secured and ranks first. This type of debt is repaid ahead of other creditors and backed by collateral. The exact terms have not been published.
The $70 million figure is also a ceiling. The words "up to" indicate that the sum will not necessarily be paid out in one go, or in full. The press release does not say what share is available on signing.
In Switzerland, loans are part of the range of options open to young companies. The startupticker.ch portal lists 70 organisations offering grants and loans throughout the life of a start-up.
How this financing compares with others in October 2026
Other young companies announced financing in October 2026, all through equity rounds. The table compares them with Distalmotion's loan. The stages and types differ: it gives an order of magnitude, not a ranking.
| Company | Type of financing | Amount | Investors named |
|---|---|---|---|
| Distalmotion | Secured term loan | Up to $70 million | Perceptive Advisors |
| Nouscom (Basel) | Series D, equity | $135 million | M Ventures and Revelation Partners (co-leads) |
| Enact Intelligence (Zurich) | Pre-seed, equity | $30 million | redalpine, Notion Capital, firstminute capital |
| Sonexos (Lausanne) | Pre-Series A, equity | CHF 5 million | Valquest Partners (lead), Bosch Ventures |
The contrast lies mainly in the nature of the money. Zurich-based start-up Enact Intelligence raises 30 million by selling shares, as does Lausanne-based Sonexos with its 5 million. Distalmotion, for its part, is financing its expansion with debt.
Swiss medtech has also been in the news this month. On 15 October 2026, Startupticker.ch summarised the progress of OxyPrem, Positrigo and MindMaze, covered in detail in our article on three milestones in Swiss medtech. Other cases can be found in our startup funding rounds section.
What we don't know yet
- The interest rate, the term of the loan and the collateral required by Perceptive Advisors have not been published.
- The share of the $70 million paid out on signing has not been specified.
- Distalmotion's previous funding rounds are not mentioned in the press release.
- The number of DEXTER systems installed in the United States and the company's revenue have not been disclosed.
- The size of the US market for ambulatory surgery centres has not been quantified.
Sources
- Startupticker.ch: Perceptive Advisors loan to Distalmotion (in English, 23 October 2026)
